Marker Therapeutics Inc. (NASDAQ:MRKR)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 1.30. At the close of trading, the stock’s price was $1.60, to imply a decrease of -3.03% or -$0.05 in intraday trading. The MRKR share’s 52-week high remains $3.77, putting it -135.62% down since that peak but still an impressive 17.5% since price per share fell to its 52-week low of $1.32. The company has a valuation of $134.51M, with an average of 0.35 million shares in intraday trading volume over the past 10 days and average of 497.96K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Marker Therapeutics Inc. (MRKR), translating to a mean rating of 1.70. Of 4 analyst(s) looking at the stock, 0 analyst(s) give MRKR a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.13.
Marker Therapeutics Inc. (NASDAQ:MRKR) trade information
After registering a -3.03% downside in the last session, Marker Therapeutics Inc. (MRKR) has traded red over the past five days. The stock hit a weekly high of 1.7300 this Friday, 10/08/21, dropping -3.03% in its intraday price action. The 5-day price performance for the stock is -4.19%, and -15.34% over 30 days. With these gigs, the year-to-date price performance is 10.34%. Short interest in Marker Therapeutics Inc. (NASDAQ:MRKR) saw shorts transact 1.35 million shares and set a 1.88 days time to cover.
Analysts on Wall Street suggest a consensus price target of $6.38, implying an increase of 74.92% to the stock’s current value. The extremes give us $5.50 and $8.00 for target low and target high price respectively. As such, MRKR has been trading -400.0% off suggested target high and -243.75% from its likely low.
Marker Therapeutics Inc. (MRKR) estimates and forecasts
Looking at statistics comparing Marker Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. Marker Therapeutics Inc. (MRKR) shares are -22.71% down over the last 6 months, with its year-to-date growth rate lower than industry average at 8.20% against 17.50%. Revenue is forecast to grow 18.80% this quarter before jumping 27.80% for the next one.
Marker Therapeutics Inc. has its next earnings report out between November 08 and November 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Marker Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Marker Therapeutics Inc. (NASDAQ:MRKR)’s Major holders
Marker Therapeutics Inc. insiders hold 19.94% of total outstanding shares, with institutional holders owning 35.68% of the shares at 44.56% float percentage. In total, 35.68% institutions holds shares in the company, led by NEA Management Company, LLC. As of Jun 29, 2021, the company held over 10.71 million shares (or 12.90% of shares), all amounting to roughly $29.89 million.
The next major institution holding the largest number of shares is Aisling Capital Management LP with 3.14 million shares, or about 3.78% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $8.77 million.
We also have USAA Mutual Fund Tr-Science & Technology Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Marker Therapeutics Inc. (MRKR) shares. Going by data provided on Jul 30, 2021, USAA Mutual Fund Tr-Science & Technology Fund holds roughly 2.38 million shares. This is just over 2.86% of the total shares, with a market valuation of $4.97 million. Data from the same date shows that the other fund manager holds a little less at 1.67 million, or 2.01% of the shares, all valued at about 4.65 million.